Positions

Overview

  • Dr. Heath is an Associate Professor of Medicine at the University of Alabama at Birmingham. She is Board-certified in Internal Medicine and Infectious Diseases. She also received a Master’s Degree in Microbiology and Immunology. Her translational laboratory is focused on investigating T and B cell biology in HIV infection and vaccine development, with external funding through NIH and CDC.  Her research program has focused on understanding 1) HIV specific CD8 T cell responses and how exhaustion, senescence, and inflammation impair immunity; 2) use of cell death and survival biomarkers to elucidate the generation and maintenance of robust anti-viral immune responses in HIV infection and vaccination; 3) accelerated aging and immunosenescence in HIV infection and the extent that mitochondrial dysfunction drives this; and 4) preservation of immune function and benefit of rapid detection and treatment of acute HIV. Dr. Heath has also developed primary HIV infection laboratories with nucleic acid amplification testing and subsequently fourth generation HIV testing for the detection of acute HIV. She also serves as the PI on the CDC funded program implementing Universal HIV Screening and linkage to care at the UAB Emergency Department with expansion to community health centers serving populations disproportionately affected by HIV. Dr. Heath is a Co-Investigator of the Alabama Vaccine Research Clinic (AVRC) and serves as PI for ongoing clinical trials for early HIV treatment and therapeutic vaccination for immune preservation. She is also active in the AIDS Clinical Trials Group (ACTG) and the HIV Vaccine Trials Network (HVTN)
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2022 Elevated CD4+T-cell glucose metabolism in HIV+ women with diabetes mellitusAIDS.  36:1327-1336. 2022
    2022 Utilizing Laboratory Results to Identify Emergency Department Patients with Indications for HIV Pre-Exposure ProphylaxisAIDS Patient Care and Stds.  36:285-290. 2022
    2022 Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concernBlood Advances.  6:3678-3683. 2022
    2021 Substance use and HIV stage at entry into care among people with HIVArchives of Public Health.  79. 2021
    2021 Characteristics of HIV Seroconverters Identified in an Emergency Department HIV Screening ProgramAIDS Patient Care and Stds.  35:255-261. 2021
    2021 Classical monocyte transcriptomes reveal significant anti-inflammatory statin effect in women with chronic HIVCardiovascular Research.  117:1166-1177. 2021
    2021 Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency 2021
    2019 Plasma levels of soluble membrane attack complex are elevated despite viral suppression in HIV patients with poor immune reconstitutionClinical and Experimental Immunology.  198:359-366. 2019
    2019 Loss of CXCR4 on non-classical monocytes in participants of the Women's Interagency HIV Study (WIHS) with subclinical atherosclerosisCardiovascular Research.  115:1029-1040. 2019
    2019 Increased influenza-specific antibody avidity in HIV-infected women compared with HIV-infected men on antiretroviral therapyAIDS.  33:33-44. 2019
    2018 Intersectional health-related stigma in persons living with HIV and chronic pain: implications for depressive symptomsAIDS Care: psychological and socio-medical aspects of AIDS-HIV.  30:66-73. 2018
    2017 Increased glucose transporter-1 expression on intermediate monocytes from HIV-infected women with subclinical cardiovascular diseaseAIDS.  31:199-205. 2017
    Impact of Glycan Positioning on HIV-1 Env Glycan Shield Density, Function, and Antibody Recognition

    Research Overview

  • HIV
    Acute HIV
    Immunology
  • Principal Investigator On

  • (CSSC-001) Convalescent Plasma to Stem Coronavirus: A Randomized Controlled Double Blinded Phase 2 Study Comparing the Efficacy and Safety of Human Coronavirus Immune Plasma (HCIP) vs. control( SARS-CoV-2 non-immune plasma) among Adults Exposed to COVID-19 and (CSSC-004) Convalescent Plasma to Stem Coronavirus: A Randomized Controlled Double Blinded Phase 2 Study Comparing the Efficacy and Safety of Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 non-immune plasma)  awarded by Johns Hopkins University
  • A5361s: Pitavastatin to Reduce Physical Function Impairment and Frailty in HIV (PREPARE)  awarded by University of California, Los Angeles
  • Ancillary Studies of NAFLD and NASH in HIV Infected Adults  awarded by Indiana University
  • Ancillary Studies of NAFLD and NASH in HIV Infected Adults - Fixed Price  awarded by Indiana University
  • Ancillary Studies of NAFLD and NASH in HIV infected Adults - Zydus Clinical Trial Aim 4  awarded by Indiana University
  • Apoptosis of HIV Vaccine Elicited B Responses as a Marker of Vaccine Durability  awarded by Hutchinson (Fred) Cancer Research Center
  • Convalescent Plasma Randomized Clinical Trials for SARS-CoV-2 Prophylaxis and Early COVID-19 Treatment are Foundational for Subsequent Hyperimmune Globulin and Vaccines  awarded by Johns Hopkins University
  • DETECT-HIV - Discovering Emerging Trends Through Enhanced Community Testing For HIV Infection  awarded by ALABAMA DEPARTMENT OF PUBLIC HEALTH
  • DETECT-HIV - Discovering Emerging Trends through Enhanced Community Testing for HIV Infection  awarded by ALABAMA DEPARTMENT OF PUBLIC HEALTH
  • DETECT-HIV - Discovering Emerging Trends through Enhanced Community Testing for HIV infection  awarded by ALABAMA DEPARTMENT OF PUBLIC HEALTH
  • DETECT-HIV – Discovering Emerging Trends through Enhanced Community Testing for HIV Infection  awarded by ALABAMA DEPARTMENT OF PUBLIC HEALTH
  • Expanded Human Immunodeficiency (HIV) Testing for Disproportionately Affected Populations  awarded by ALABAMA DEPARTMENT OF PUBLIC HEALTH
  • Expanded Human Immunodeficiency (HIV) Testing for Disproportionately Affected Populations  awarded by ALABAMA DEPARTMENT OF PUBLIC HEALTH
  • Expanded Human Immunodeficiency (HIV) Testing for Disproportionately Affected Populations  awarded by ALABAMA DEPARTMENT OF PUBLIC HEALTH
  • Expanded Human Immunodeficiency (HIV) Testing for Disproportionately Affected Populations  awarded by ALABAMA DEPARTMENT OF PUBLIC HEALTH
  • Expanded Human Immunodeficiency Virus (HIV) Testing for Disproportionately Affected Populations  awarded by ALABAMA DEPARTMENT OF PUBLIC HEALTH
  • Expanded Human Immunodeficiency Virus (HIV) Testing for Disproportionately Affected Populations  awarded by ALABAMA DEPARTMENT OF PUBLIC HEALTH
  • Expanded Human Immunodeficiency Virus (HIV) Testing for Disproportionately Affected Populations  awarded by ALABAMA DEPARTMENT OF PUBLIC HEALTH
  • Expanded Human Immunodeficiency Virus (HIV) Testing for Disproportionately Affected Populations  awarded by ALABAMA DEPARTMENT OF PUBLIC HEALTH
  • Getting to Zero Among Black MSM in the American South  awarded by FHI 360
  • Integrated HIV Surveillance and Prevention Programs for Health Departments  awarded by ALABAMA DEPARTMENT OF PUBLIC HEALTH
  • Integrated HIV Surveillance and Prevention Programs for Health Departments  awarded by ALABAMA DEPARTMENT OF PUBLIC HEALTH
  • Integrated HIV Surveillance and Prevention Programs for Health Departments  awarded by ALABAMA DEPARTMENT OF PUBLIC HEALTH
  • National Center for HIV-AIDS, Viral Hepatitis, STD, and TB Prevention Integrated HIV Surveillance and Prevention Programs for Health Departments  awarded by ALABAMA DEPARTMENT OF PUBLIC HEALTH
  • National Center for HIV-AIDS, Viral Hepatitis, STD, and TB Prevention Integrated HIV Surveillance and Prevention Programs for Health Departments  awarded by ALABAMA DEPARTMENT OF PUBLIC HEALTH
  • On the Pathogenic Role of Anti-CD4+ Tcell Recovery After Antiretroviral Therapy in HIV Disease  awarded by Medical University of South Carolina
  • Private Grant  awarded by MERCK & COMPANY, INC. ^
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by GEO VAX, INC.
  • Private Grant  awarded by GENECURE BIOTECHNOLOGIES, LLC
  • Private Grant  awarded by ICHOR MEDICAL SYSTEMS INC
  • Private Grant  awarded by REGENERON PHARMACEUTICALS, INC.
  • Private Grant  awarded by REGENERON PHARMACEUTICALS, INC.
  • Private Grant  awarded by PPD INVESTIGATOR SERVICES, LLC.
  • Private Grant  awarded by GlaxoSmithKline
  • Private Grant  awarded by GlaxoSmithKline
  • Private Grant  awarded by Janssen
  • Regional AIDS Education and Training Centers-Base  awarded by Emory University
  • Regional AIDS Education and Training Centers-MAI  awarded by Emory University
  • Survival Factors Regulating the HIV-Specific Cytotoxic T Lymphocyte Response  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • UAB Center for AIDS Research - Diversity Supplement (HEATH)  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • UAB Center for AIDS Research - The Role of HIV-Infection and Antiretroviral Therapy Related Mitochondrial Toxicity in Accelerated Aging  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • Investigator On

  • A-Z Clinical Trials Unit  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • A-Z Clinical Trials Unit  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • A5391- Doravirine for Persons with Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)  awarded by University of California, Los Angeles
  • AIDS Clinical Trials Group: Protocol Funds  awarded by Brigham and Women's Hospital
  • AIDS Clinical Trials Group: Protocol Funds FTE Funding  awarded by Brigham and Women's Hospital
  • Alabama - Clinical Trials Unit  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • Alabama Clinical Trials Unit (CTU)  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • CFAR Network of Integrated Clinical Systems (CNICS)  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • Chronic Widespread Pain in HIV: Novel Mechanisms and Therapeutics  awarded by National Institute on Drug Abuse/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant - Administrative Supplement to Stimulate Research in HIV/AIDS Cancer Research  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant - Administrative Supplement to Stimulate Research in HIV/AIDS Cancer Research  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant - Administrative Supplement to Stimulate Research in HIV/AIDS Cancer Research  awarded by National Cancer Institute/NIH/DHHS
  • HPTN 078: Enhancing Recruitment, Linkage to Care and Treatment for HIV-Infected Men Who Have Sex with Men (MSM) in the United States  awarded by FAMILY HEALTH INTERNATIONAL
  • HPTN 083-A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men (ViiV)  awarded by FAMILY HEALTH INTERNATIONAL
  • HPTN Personal Protective Equipment- HPTN Studies  awarded by FAMILY HEALTH INTERNATIONAL
  • HPTN Unanticipated Clinical Trials Costs  awarded by FAMILY HEALTH INTERNATIONAL
  • HVTN 703/HPTN 081 Protocol Funding (PF)  awarded by Hutchinson (Fred) Cancer Research Center
  • HVTN Protocol Funding (PF)  awarded by Hutchinson (Fred) Cancer Research Center
  • HVTN Protocol Funding (PF)  awarded by Hutchinson (Fred) Cancer Research Center
  • Matrikines and COPD-PH COVID-19  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • NIAID-Fred Hutch-Janssen Collaboration CTU/Clinical Trial Site Activities for HVTN 117/118  awarded by Hutchinson (Fred) Cancer Research Center
  • Neutrophil-Mediated Immune Suppression as a Mechanism of HIV-1 Pathogenesis  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by GENOCEA BIOSCIENCES, INC.
  • Private Grant  awarded by BAVARIAN NORDIC A/S
  • Private Grant  awarded by VICAL, INC.
  • Private Grant  awarded by BAVARIAN NORDIC A/S
  • Private Grant  awarded by GENOCEA BIOSCIENCES, INC.
  • Private Grant  awarded by GlaxoSmithKline
  • Private Grant  awarded by GENOCEA BIOSCIENCES, INC.
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by MERCK & COMPANY, INC. ^
  • Private Grant  awarded by GENOCEA BIOSCIENCES, INC.
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by JANSSEN R&D IRELAND
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by BIODTECH, INC
  • Private Grant  awarded by VIIV HEALTHCARE COMPANY
  • Private Grant  awarded by VIIV HEALTHCARE COMPANY
  • Private Grant  awarded by VIIV HEALTHCARE COMPANY
  • Private Grant  awarded by VICAL, INC.
  • Private Grant  awarded by PROTEUS DIGITAL HEALTH, INC.
  • Private Grant  awarded by GlaxoSmithKline
  • Private Grant  awarded by ROCHE DIAGNOSTICS OPERATIONS INC
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by BAVARIAN NORDIC A/S
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by GlaxoSmithKline
  • Private Grant  awarded by MERCK SHARP & DOHME CORP
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by MERCK SHARP & DOHME CORP
  • Private Grant  awarded by Janssen
  • Training in Primary Care Medicine and Dentistry: Physician Assistant Training in Primary Care  awarded by Health Resources and Services Administration/DHHS
  • UAB Center for AIDS Research  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • UAB Center for AIDS Research  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • UAB Center for AIDS Research (CFAR)  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • UAB Center for AIDS Research (CFAR) - A Dynamic COVID-19 Community-Engaged Testing Strategy in Alabama (COVID COMET AL)  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • UAB Center for AIDS Research (CFAR) - Mobile Testing to Increase HIV-testing Uptake in Rural Alabama: A Pilot Implementation Project (MOBILISE)  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • UAB Center for AIDS Research - Clinical Core C  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • UAB Center for AIDS Research - Core C - Clinical Core  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • UAB Center for AIDS Research - The Detrimental Nexus of HCV and HIV Infection on Bioenergetics and Immune Function  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • UAB Center for AIDS Research - Using Big Data to Estimate Undiagnosed HIV Infection and Inform Testing Interventions in Alabama  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • UAB Center for Clinical and Translational Science (CCTS) (3 Linked Awards UL1, KL2, TL1)  awarded by National Center for Advancing Translational Sciences/NIH/DHHS
  • UAB Institutional Career Development Program in HIV-Related Heart, Lung, Blood and Research  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • UAB-MISS MACS/WIHS Combined Cohort Study (MACS/WIHS-CCS)  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Unsolicited R24 CFAR Network of Clinical Systems (CNICS)  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • Unsolicited R24 for the CFAR-Network of Integrated Clinical Sciences, CNICS  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • VVTEU Protocol Development and Implementation for Task Areas B-C Phase II Vaccine Trial for Influenza (“Flu Pandemic” or “H7”)  awarded by VANDERBILT UNIVERSITY MEDICAL CENTER ^
  • Vaccine and Treatment Evaluation Units  awarded by VANDERBILT UNIVERSITY MEDICAL CENTER ^
  • Vaccine and Treatment Evaluation Units - Admin Task  awarded by VANDERBILT UNIVERSITY
  • Education And Training

  • UAB Hospital, Internship
  • UAB Hospital, Residency
  • UAB Hospital, Postdoctoral Fellowship
  • Doctor of Medicine, Virginia Commonwealth University 2000
  • Full Name

  • Sonya Heath